Effect of Co-Administration of Rivaroxaban and Clopidogrel on Bleeding Time, Pharmacodynamics and Pharmacokinetics: A Phase I Study

por Kubitza, Dagmar, Becka, Michael, Mück, Wolfgang, Schwers, Stephan
Publicado 2012

Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban

por Mueck, Wolfgang, Stampfuss, Jan, Kubitza, Dagmar, Becka, Michael
Publicado 2013

Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects

por Kubitza, Dagmar, Becka, Michael, Mück, Wolfgang, Krätzschmar, Jöern
Publicado 2014

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)

por Frey, Reiner, Mueck, Wolfgang, Becka, Michael, Kraetzschmar, Joern, Wensing, Georg
Publicado 2011

Topical administration of regorafenib eye drops: phase I dose‐escalation study in healthy volunteers

por Zimmermann, Torsten, Höchel, Joachim, Becka, Michael, Boettger, Michael K., Rohde, Beate, Schug, Barbara, Kunert, Kathleen S., Donath, Frank
Publicado 2018

Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study

por Kubitza, Dagmar, Willmann, Stefan, Becka, Michael, Thelen, Kirstin, Young, Guy, Brandão, Leonardo R., Monagle, Paul, Male, Christoph, Chan, Anthony, Kennet, Gili, Martinelli, Ida, Saracco, Paola, Lensing, Anthonie W. A.
Publicado 2018